Nerviano Medical Sciences has actively participated in the XXVI annual meeting of the Division of Pharmaceutical Chemistry of the Italian Chemical Society (SCI) held in Milan between 16 and 19 July, in the evocative seat of the State University, at the "Cá Granda".
During the scientific meeting, organized in two parallel sessions, a researcher of the Nerviano Campus presented by an oral communication the research process that led to the identification of NMS-P945, a proprietary drug based on a thienoindolic derivative, suitable for the production of conjugated antibodies.
The presentation was very successful, not only because illustrating the process of asymmetric synthesis of the active principle, the related biochemical data and the promising results obtained in preclinical models, but also because it allowed to present an innovative research approach, still little known in Italy, dedicated to the development of new oncological drugs.
Nerviano Medical Sciences has been working for several years trying to limit the lack of selectivity of cytotoxic agents through their coupling to antibodies to form an "Antibody-Drug Conjugate" (ADC) that specifically recognizes a target antigen expressed on the cell surface that either unique or expressed at higher levels in cancer cell lines than in normal tissues.
The drug-linkers created in the research center, in fact, have an innovative and peculiar mechanism of action (DNA binding and alkylation) and represent the perfect balance between high cytotoxic potencies and conjugability.
This approach represents one of the platforms of the Nerviano center dedicated to new targeted therapies, which include a set of technologies, knowledge, molecules, experimental models and patents and which allow the development of innovative and highly effective drugs.